A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.